StockData

Longeveron vs China SXT Pharmaceuticals

LGVN and SXTC side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How LGVN and SXTC compare

China SXT Pharmaceuticals grew revenue faster over the last twelve months (−34.6% versus −42.7% for Longeveron).

China SXT Pharmaceuticals keeps more of each dollar of sales as profit, with a net margin of −545% compared with −1978% at Longeveron.

Longeveron scores higher on the StockData Score (5 against 4 for China SXT Pharmaceuticals), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricLGVNSXTC
Size and price
Market cap$67.3M–
Share price$2.11$2.86
Change, 1 year−69.0%−100.0%
Change, 5 years−99.9%−100%
Beta (5Y)1.44–
Employees3756
StockData Score
Total score5 (better)4
Valuation score00
Growth score01 (better)
Performance score01 (better)
Health score5 (better)2
Dividend score00
Valuation
P/S56.7×–
P/B6.5×–
FCF yield−30.5%–
Growth
Revenue growth (TTM)−42.7%−34.6% (better)
Revenue growth, 5Y average−26.6%−24.9% (better)
Profitability
Gross margin69.8% (better)21.9%
Operating margin−1993%−626% (better)
Net margin−1978%−545% (better)
FCF margin−1730%–
Return on equity−204%−27.5% (better)
Return on invested capital−1412% (better)−1657%
Financial health
Debt / equity0.000.03 (better)
Interest coverage–−113.1×
Current ratio2.637.93 (better)
Altman Z-score−9.42–
Piotroski F-score13 (better)
Dividends and buybacks
Shareholder yield0.00%–
Ownership
Held by institutions1.5%–
Held by insiders43.8%0.00%
Short interest, % of float0.88%2.9%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.